No, brompheniramine allergy is NOT a contraindication to DuoNeb
A brompheniramine allergy does not contraindicate the use of DuoNeb (albuterol/ipratropium bromide). These are chemically distinct medications with different mechanisms of action and no cross-reactivity.
Why This Is Safe
Chemical Structure Differences
- Brompheniramine is an alkylamine antihistamine (H1-receptor antagonist) used for allergic symptoms
- Ipratropium bromide is a quaternary ammonium anticholinergic bronchodilator
- Albuterol is a beta-2 adrenergic agonist bronchodilator
These three drug classes have completely different chemical structures and pharmacologic mechanisms. There is no structural similarity that would predict cross-reactivity.
FDA Labeling Guidance
According to the FDA drug label, ipratropium bromide is contraindicated only in cases of "known or suspected hypersensitivity to ipratropium bromide, or to atropine and its derivatives" 1. Brompheniramine is not mentioned as a contraindication, nor is it an atropine derivative.
The label specifically notes that "allergic-type reactions such as skin rash, angioedema of tongue, lips and face, urticaria, laryngospasm and anaphylactic reaction have been reported" with ipratropium, and that "many of the patients had a history of allergies to other drugs and/or foods" 1. This indicates that while patients with multiple drug allergies may be at higher risk for reactions, there is no specific cross-reactivity pattern with antihistamines.
Clinical Considerations
When to Use Caution
- Patients with documented hypersensitivity to atropine or atropine derivatives (structurally related to ipratropium)
- Patients with documented allergy to albuterol or other beta-agonists
- Patients with multiple drug allergies (general increased risk, not specific contraindication)
Appropriate Use
DuoNeb is indicated for bronchodilation in COPD and asthma exacerbations. Guidelines support its use, particularly noting that ipratropium bromide provides additive benefit to short-acting beta-agonists in moderate or severe exacerbations in the emergency care setting 2.
You can safely administer DuoNeb to a patient with brompheniramine allergy. Monitor for any allergic reaction as you would with any medication, but there is no pharmacologic basis to withhold this treatment based on antihistamine allergy alone.